Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer

Molecular Carcinogenesis

Volumn 48, Issue 9, 2009, Pages 790-800

  Misra, Chaitali ^a   Majumder, Mousumi ^b   Bajaj, Swati ^a   Ghosh, Saurabh ^b   Roy, Bidyut ^b   Roychoudhury, Susanta ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b INDIAN STATISTICAL INSTITUTE   (India)

Author keywords

Genetic susceptibility; Genotype combination; Oral cancer risk; Tobacco use

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN P73; DNA BINDING PROTEIN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ALLELE; APOPTOSIS; ARTICLE; CANCER RISK; CELL CYCLE; CODON; CONTROLLED STUDY; DNA REPAIR; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRIORITY JOURNAL; PROMOTER REGION; SMOKING HABIT; TOBACCO; ADULT; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; MIDDLE AGED; MOUTH TUMOR; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKELESS TOBACCO; SMOKING;

NICOTIANA TABACUM;

ADULT; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKOPLAKIA; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NUCLEAR PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS; SMOKING; TOBACCO, SMOKELESS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 69049099383     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20523     Document Type: Article

References (58)

1. WHO. Global facts on tobacco or oral health; 2007.
2. OCF. Oral cancer foundation; 2008.
3. Petersen PE. Strengthening the prevention of oral cancer: The WHO perspective. Community Dent Oral Epidemiol 2005;33:397-399. (Pubitemid 43906606)
4. Stewart BW, Kleihues P. World cancer report. Lyon: WHO International Agency for Research on Cancer 2003.pp. 1-351.
5. Daftary DK, Murti PR, Bhonsle RB, Gupta PC, Mehta FS. Oral cancer. In: Johnson NW, editor. Risk markers for oral diseases. Vol.2. Cambridge: Cambridge University Press; 1991.pp. 29-63.
6. Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia? Oral Oncol 2003;39:470-475.
7. Mishra M, Mohanty J, Sengupta S, Tripathy S. Epidemiological and clinicopathological study of oral leukoplakia. Indian J Dermatol Venereol Leprology 2005;71:161-165. (Pubitemid 40898198)
8. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
9. Kaelin WG, The p53 gene family. Oncogene 1999;18:7701-7705.
10. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998;4:839-843. (Pubitemid 28331028)
11. Jost CA, Marin MC, Kaelin WG, p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997;389:191-194.
12. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819. (Pubitemid 27357971)
13. Han S, Semba S, Abe T, et al. Infrequent somatic mutations of the p73 gene in various human cancers. Eur J Surg Oncol 1999;25:194-198. (Pubitemid 29182464)
14. El-Naggar AK, Lai S, Clayman GL, et al. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis 2001;22:729-735. (Pubitemid 32447920)
15. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK.Differential expression of p53 gene familymembers p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002;33:158-164. (Pubitemid 34298729)
16. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003;13:49-58.
17. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein-Thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;59:1-7.
18. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-2234. (Pubitemid 23156805)
19. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602. (Pubitemid 39535748)
20. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299. (Pubitemid 27220766)
21. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.
22. Lohrum MA, Vousden KH. Regulation and function of the p53-related proteins: Same family, different rules. Trends Cell Biol 2000;10:197-202.
23. Wang XQ, Ongkeko WM, Lau AW, Leung KM, Poon RY. A possible role of p73 on themodulation of p53 level through MDM2. Cancer Res 2001;61:1598-1603.
24. Mitra S, Sikdar N, Misra C, et al. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int J Cancer 2005;117:786-793. (Pubitemid 41598830)
25. Kang MJ, Park BJ, Byun DS, et al. Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clin Cancer Res 2000;6:1767-1771.
26. Hamajima N, Matsuo K, Suzuki T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002;181:81-85. (Pubitemid 34326437)
27. Hamajima N, Saito T, Matsuo K, Kozaki K, Takahashi T, Tajima K. Polymerase chain reaction with confronting twopair primers for polymorphismgenotyping. Jpn J Cancer Res 2000;91:865-868. (Pubitemid 30774558)
28. Schoonjans F. Medcalc Software. ed.7.4; 1993.
29. Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer 2001;85:1499-1503. (Pubitemid 34001580)
30. Li G, Sturgis EM, Wang LE, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 2004;25:1911-1916. (Pubitemid 39405910)
31. Li G, Wang LE, Chamberlain RM, Amos CI, Spitz MR, Wei Q. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res 2004;64:6863-6866. (Pubitemid 39330992)
32. Niwa Y, Hirose K, Matsuo K, et al. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. Cancer Lett 2005;219:183-190. (Pubitemid 40269482)
33. Pfeifer D, Arbman G, Sun XF. Polymorphismof the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis 2005;26:103-107. (Pubitemid 40207704)
34. Niwa Y, Hamajima N, Atsuta Y, et al. Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer Lett 2004;205:55-60. (Pubitemid 38230139)
35. Choi JE, Kang HG, Chae MH, et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet 2006;44:543-550.
36. Li C, Chen K, Liu Z, et al. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol 2008;128:1585-1588. (Pubitemid 351693182)
37. Ge H, Wang YM, Cao YY, et al. The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis Esophagus 2007;20:290-296. (Pubitemid 47054757)
38. Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associatedwith a reduced risk of lung cancer in a Chinese population. Int J Cancer 2005;114:455-460. (Pubitemid 40279969)
39. Li H, Yao L, Ouyang T, et al. Association of p73 G4C14-to- A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 2007;28:372-377. (Pubitemid 46321853)
40. Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer (Tokyo, Japan) 2003;10:307-311.
41. Jun HJ, Park SH, Lee WK, et al. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog 2007;46:100-105. (Pubitemid 46272118)
42. Schabath MB, Wu X, Wei Q, Li G, Gu J, Spitz MR. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:158-161.
43. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: A combined analysis. Carcinogenesis 2007;28:2262-2267. (Pubitemid 350119563)
44. Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: Evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007;16:2717-2723. (Pubitemid 351196328)
45. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants ofwild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100. (Pubitemid 29046852)
46. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961-963. (Pubitemid 17004567)
47. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-199. (Pubitemid 37541770)
48. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy viamodulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402. (Pubitemid 38340307)
49. Dumont P, Leu JI, Della Pietra AC , George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genet 2003;33:357-365. (Pubitemid 36278852)
50. Schneider-Stock R, Mawrin C, Motsch C, et al. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer. Am J Pathol 2004;164:1233-1241. (Pubitemid 38387790)
51. Mitra S, Banerjee S, Misra C, et al. Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. J Clin Pathol 2007;60:1040-1047. (Pubitemid 47441939)
52. Marin MC, Jost CA, Brooks LA, et al. A common polymorphismacts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47-54.
53. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nature Rev 2002;2:605-615.
54. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000;404:99-103. (Pubitemid 30143141)
55. Grob TJ, Novak U, Maisse C, et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 2001;8:1213-1223. (Pubitemid 34048476)
56. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science (New York, NY) 2000;289:304-306.
57. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 2002;62:3598-3602.
58. Zaika AI, Slade N, Erster SH, et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 2002;196:765-780.